Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187649 | 0.85 | EGFR (0.48) | EGFRPIK3CDPIK3CATDO2 | |
| SCHEMBL2078225 | 0.71 | ALDH1A1 (0.50) | — | |
| SCHEMBL2986767 | 0.68 | CYP19A1 (0.33) | IMPDH2 | |
| SCHEMBL2989390 | 0.68 | PRKCZ (0.35) | IMPDH2 | |
| SCHEMBL16014058 | 0.68 | ALDH1A1 (0.41) | EGFR | |
| Quinazoline SCHEMBL29356169 | 0.66 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2IMPDH2 | |
| Quinazoline SCHEMBL5920 | 0.66 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2IMPDH2 | |
| Quinazoline SCHEMBL29490398 | 0.66 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2IMPDH2 | |
| Quinazoline SCHEMBL22833783 | 0.66 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2IMPDH2 | |
| Quinazoline SCHEMBL3533306 | 0.64 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| EP-2146988-B1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-05-27 | — | — | US | disclosed |
| EP-2146988-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | Almirall, S.A. (ES) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | MAPK8, MAPK4, MAP3K8 | EGFR 1264/4885PIK3CD 180/4885PIK3CA 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.